Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 2/20 | 0.65 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299224 | 0.83 | FEN1 (0.73) | FEN1GRM4ADORA2BALDH1A1EGFR | |
| SCHEMBL13322658 | 0.82 | FEN1 (0.46) | FEN1GRM4ADORA2BCCNA2CDK2 | |
| SCHEMBL18687483 | 0.79 | FEN1 (1.00) | FEN1GRM4ADORA2BPDE4APDE4B | |
| SCHEMBL29960173 | 0.79 | FEN1 (1.00) | FEN1GRM4ADORA2BPDE4APDE4B | |
| SCHEMBL22038880 | 0.79 | ADORA2B (0.45) | FEN1GRM4ADORA2BCCNA2CDK2 | |
| SCHEMBL30057361 | 0.77 | FEN1 (0.51) | FEN1GRM4CCNA2CDK2PDE4A | |
| SCHEMBL22016238 | 0.76 | FEN1 (0.63) | FEN1GRM4PDE4APDE4BPDE4C | |
| SCHEMBL16640325 | 0.75 | CCNA2 (0.46) | FEN1GRM4CCNA2CDK2PDE4A | |
| SCHEMBL22017690 | 0.74 | GRM4 (0.45) | FEN1GRM4ADORA2BALDH1A1 | |
| SCHEMBL16352662 | 0.73 | ERCC1 (0.61) | FEN1GRM4ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | FEN1 4830/4885GRM4 1490/4885ADORA2B 1487/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | FEN1 4830/4885GRM4 1490/4885ADORA2B 1487/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | FEN1 4828/4885GRM4 2063/4885ADORA2B 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.